Paclitaxel Polymersomes + Carboplatin + Adebelimab: Neoadjuvant Phase Ⅱ Single-Arm Study for Resectable Mucosal Melanoma

This study is testing a combination of three drugs — paclitaxel polymersomes (a new formulation of a chemotherapy drug), carboplatin, and adebelimab (an immunotherapy drug) — given before surgery (neoadjuvant treatment) in patients with resectable mucosal melanoma (a rare type of melanoma that occurs inside body cavities like the mouth, nose, or digestive tract). **You may be eligible if...** - You are 18 or older - You have confirmed resectable mucosal melanoma - You have not previously received immunotherapy (e.g., anti-PD-1 or anti-CTLA-4 drugs) or taxane-based chemotherapy - Your overall health is good (ECOG 0–1) and your blood counts and organ function meet the required thresholds **You may NOT be eligible if...** - You have received prior checkpoint immunotherapy or taxane chemotherapy - You have had immunosuppressant medications in the past 6 months - Your blood counts or organ function do not meet study requirements - You are pregnant Talk to your doctor to see if this trial is right for you.